FDA approves Roivant drug for rare autoimmune skin disease

The FDA just greenlit a new drug from Roivant and its subsidiary Priovant for dermatomyositis, a rare autoimmune disease. This medicine targets a specific pathway that drives skin and muscle inflammation, offering a new option for patients with limited treatments.